<DOC>
	<DOC>NCT01257451</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of vildagliptin 50 mg bid in elderly patients with Type 2 Diabetes Mellitus (T2DM).</brief_summary>
	<brief_title>Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>age: ≥ 70 years inclusive at Visit 1. patients with a confirmed diagnosis of T2DM HbA1c of ≥ 7% and ≤10.0% by central laboratory at Visit 1 and assessed by the investigator to be inadequately controlled body mass index (BMI) in the range of 1945kg/m2 FPG ≥ 270 mg/dL (≥ 15.0 mmol/L) previous or current participation in any vildagliptin clinical study. history of hypersensitivity to DPP4 inhibitors. concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study. donation of blood or significant blood loss equaling to at least one unit of blood within the past 2 weeks of start of study or a blood transfusion within the past 12 weeks or planned regular transfusions during the study period Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Type 2 Diabetes Mellitus, Vildagliptin, Elderly Patients</keyword>
</DOC>